IMNN: First Site Activated for Phase 3 OVATION 3 Trial
On May 12, 2025, Imunon, Inc. (IMNN) announced financial results for the first quarter of 2025 and provided a business update. The company...
234 Views
IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer
On March 25, 2025, Imunon, Inc. (IMNN) held a conference call to discuss the finalized protocol for a Phase 3 clinical trial of IMNN-001 in...
393 Views
IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025
On February 27, 2025, Imunon, Inc. (IMNN) announced financial results for 2024 and provided a business update. The company is currently finishing...
453 Views
IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25
Imunon, Inc. (IMNN) is finishing preparations to initiate a Phase 3 clinical trial of its lead development compound, IMNN-001, in the treatment of...
273 Views
IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001
On November 25, 2024, Imunon, Inc. (IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) on its proposed plan...
303 Views